TNXP On December 8, 2016, the Company issued a press release announcing that the Company presented an updated poster, entitled, “The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX-102 SL in the Treatment of Military-Related PTSD” (the “Poster”), at the 55 th Annual Meeting of the American College of Neuropsychopharmacology held in Hollywood, Florida. The Poster was presented by Dr. Gregory Sullivan, M.D., the Company’s chief medical officer.
A copy of the press release that discusses this matter is filed as Exhibit 99.03 to, and incorporated by reference in, this report. The foregoing description of the Poster is qualified in its entirety by reference to the Poster, a copy of which is deemed filed as Exhibit 99.02 to, and is incorporated by reference in, this report.
The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.01 Corporate Presentation by the Company for December 2016*
99.02 The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX-102 SL in the Treatment of Military-Related PTSD Poster, filed as an exhibit to the Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 7, 2016 and incorporated herein by reference*
99.03 Press Release, dated December 8, 2016, issued by Tonix Pharmaceuticals Holding Corp.*
$TNXP
Surrounded by thieves, lets fight our way out!
